The NU Zombie Research Facility has discovered a new stranded virus called Z1H1, which is a combination of an H5N1 and zombie virus. The respiratory infection caused by the virus is serious and leads to a rapid and painful death. The UN Zombie Research Facility has initiated a project to design a preventative vaccine and defeat the zombie virus in this battle. The latest technologies available at NU's zombie research facility offer the opportunity to engineer viral particles (VLPs). Since a preventive vaccine is desired, exposure to very similar viruses or parts thereof will lead to maximum immunogenicity (example can be the Spanish flu pandemic). Therefore, the N1 neuraminidase subtype of the exact H5N1 virus that is involved in the zombie virus produced by antigenic shift is introduced into VLPs. VLPs are proposed to trigger the innate immune response resulting in opsonization via C3b, via an alternative pathway that triggers the classical pathway of the innate immune system. As a result, opsonized particles will be collected via CR1 and CR2 from DCs to introduce into the adaptive immune system, and CR1 onto erythrocytes and delivered for destruction. The problem is that the humoral response will not be effective unless the Fc regions of Ig are bound to another molecule. The idea was to develop Ig (such as dimeric IgA and pentameric IgM) against the zombie virus and the receptor that will recognize some parts of the Ig attached to the antigen and the J chain that will undergo a conformation change after binding to the antigen. pIg (dimeric IgA and pentameric IgM) bound to Z1H1 will undergo a conformational change in its geometry. The pig is expected to bend and cause changes in conformation. Consequently, a change is expected in the J chain which can act as a receptor for another Ig and used for labeling to eliminate zomb... in the center of the paper... and in various pH ranges. The vaccine primarily activates mucosal tissue (MALT) and will not be as effective in tissue fluid (plasma). The designed vaccine can induce a strong and long-lasting immune response, however, due to point mutations, vaccination could be changed every season. Works Cited Brandtzaeg, P. (2007). Induction of secretory immunity and memory on mucosal surfaces. Vaccine, 25(30), 5467-5484. Clements, M. L., & Murphy, B. R. (1986). Development and persistence of local and systemic antibody responses in adults treated with live attenuated or inactivated influenza A virus vaccine. Journal of Clinical Microbiology, 23(1), 66-72.Tausk, F. and Gigli, I. (1990). The human C3b receptor: function and role in human diseases. Journal of Investigative Dermatology, 94Woof, J. M., & Kerr, M. A. (2004). IgA function – variations on a theme. Immunology, 113(2), 175-177.